JP6231633B2 - Microneedle for dental material transmission that is flexible to fit the curvature of the gums and method for producing the same - Google Patents

Description

  The present invention relates to a microneedle for transmitting a dental substance and a manufacturing method thereof, and more particularly, can be attached to a gum formed by a curved surface and transmits the dental substance to the inside of the gum. The present invention relates to a microneedle for dental substance transmission and a method for manufacturing the same.

  As a conventional method for administering a transdermal drug in dental treatment, a method of penetrating the oral endothelium using a syringe has been mainly used. However, such a method has a problem of causing the patient to induce extreme stress along with pain.

  Recently, in order to solve such problems, research on microneedles, which is a new transdermal transmission system, has been activated. In general, a microneedle is a device that stimulates the skin by using a small needle, supplies a nutrient through a small hole in the skin, and easily penetrates the drug. The form is not particularly limited as long as it can penetrate, but has a diameter of about 1 μm to 100 μm.

  In particular, when such microneedles are used, drugs can be transmitted without causing pain to cells or local areas of the organization, and penetration into biological membranes such as peptides, proteins, oligonucleotides, and DNA is not possible. Possible molecules can be administered and are also useful when delivering drugs to a target at sites that are difficult to treat and at specific sites or organizations in the body.

  There are four types of microneedles such as solid microneedles, coating microneedles, soluble microneedles, and hollow microneedles.

  Among these, the soluble microneedle is a system in which the encapsulated drug is transmitted into the skin while the microneedle substance is dissolved after administration to the skin. There is an advantage that there is no risk of contamination since the drug can be transmitted by one puncture and the microneedle does not remain.

  However, the microneedles require a long time of 10 minutes or more to be dissolved by moisture in the skin after administration, and the active ingredient contained in the microneedles depends on the complete melting of the microneedles. For this reason, there is a problem that a fixed amount of drug is difficult to be transmitted to the skin. Furthermore, since the production of soluble microneedles is based on molding, there are also problems that the production time is long and the active ingredient changes depending on the production temperature.

  On the other hand, in the case of coated microneedles, manufacturing is simple and the drug is coated on the surface of the needle, so that the drug can be transmitted quickly, but the needle remains, There is a limit of danger.

  Since conventional soluble microneedles or coated microneedles were mainly applied to flat skin, there was a limit to application to gums in the oral cavity having an irregular bent shape.

  The present invention relates to a microneedle for transmitting a dental substance that can be attached to a gum formed on a bent surface because the substrate shape of the microneedle is bent into a shape corresponding to the gum shape inside the oral cavity, and a method for manufacturing the microneedle. The purpose is to provide.

  In addition, the present invention can rapidly transfer a quantitative amount of an active ingredient when the needle is administered to the oral endothelium by coating a substance containing an active ingredient on a water-soluble microneedle containing a drug. Another object of the present invention is to provide a microneedle for dental substance transmission and a method for manufacturing the same.

  Another object of the present invention is to provide a microneedle and a method for manufacturing the microneedle that can transmit a fixed amount of an active ingredient within a short time with a minimum number of administrations.

  Furthermore, the present invention provides a safe microneedle that is manufactured so that the microneedle is water-soluble and partly or entirely melts after administration to the skin, and thus there is no risk of contamination after dental treatment, and its manufacture. Yet another object is to provide a method.

  A dental substance transmission microneedle according to an embodiment of the present invention includes a needle body portion, an active ingredient coating portion that is coated on the surface of the needle body portion and includes an active ingredient that is transmitted to an oral endothelium structure, A base part that is coupled with the needle body part and bends along the skin shape inside the oral cavity, and the base part includes polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), and polymethacrylic acid. Methyl (PMMA), ethylene vinyl acetate (EVA), polycaprolactone (PCL), polyurethane (PU), polyethylene terephthalate (PET), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycol Acid copolymer (PLGA) and polyglycola De may include at least one selected from the group consisting of (PGA).

  The base portion is made of polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polyurethane (PU), polyethylene terephthalate (PET). ), Polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA), and polycaprolactone (PCL) ) In a ratio of 1: 9 to 5: 5% by weight.

  The base portion is made of polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polyurethane (PU), polyethylene terephthalate (PET). ), Polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA), and polycaprolactone (PCL) ) May be included at a ratio of 1: 9 to 2: 8% by weight.

  The base portion may include lactic acid-glycolic acid copolymer (PLGA) and polycaprolactone (PCL) in a ratio of 1: 9 to 5: 5% by weight.

  In addition, the needle body may include a thickener and an active ingredient that is transmitted to the oral endothelium.

  Further, the thickener contained in the needle body may be carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran ( Sulfuric acid), chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyhydride, polyhydride , Polyetherester, polyester ester Polyesteramide, poly (butyric acid), poly (valeric acid), polyacrylate, poly (ethylene-vinyl acetate) polymer, acrylic-substituted cellulose acetate, poly (vinyl chloride), Polyvinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), ethyl cellulose (EC), cellulose HPC), carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, isomaltose, isomaltose ), A copolymer of monomers that form these polymers, and at least one selected from the group consisting of cellulose.

  In addition, the active ingredient coating portion may include a thickener and an active ingredient that is transmitted to the oral endothelial tissue.

  Further, the thickener contained in the active ingredient coating part is carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran. (Sulfuric acid), chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyhydride, polyhydride ), Polyetherester, polyester Teramide (polyesteramide), poly (butyric acid), poly (valeric acid), polyacrylate (polyacrylate), ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, polyvinyl chloride (Polyvinyl Chloride), Polyvinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), ethyl cellulose (EC), SE Loin (HPC), carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose (Lactulose), a copolymer of monomers forming these polymers, and at least one selected from the group consisting of cellulose may be included.

  Further, the needle main body part and the active ingredient coating part contain a thickener, and the thickener contained in the active ingredient coating part is more soluble than the thickener than the water content of the thickener contained in the needle main body part. Solubility may be even greater.

  In addition, carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran contained in the needle body and the active ingredient coating part. (Sulfuric acid), chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyhydride, polyhydride ), Polyetherester (polyetherest) r), polyesteramide (polyesteramide), poly (butyric acid), poly (valeric acid), polyacrylate, poly (ethylene-vinyl acetate), ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, polyvinyl chloride (Polyvinyl) Chloride), polyvinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide (PVP), polyvinyl pyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC) , Hydroxy At least one of cyclopropylcellulose (HPC), carboxymethyl cellulose, and cyclodextrin is used as a first thickener, and maltose contained in the needle body and the active ingredient coating portion, When at least one of lactose, trehalose, cellobiose, isomaltose, turanose and lactulose is used as the second thickener, the active ingredient coating part The ratio of the weight percent of the second thickener to the first thickener in the first thickener is relative to the first thickener in the needle body. That may be even greater than the weight percentage of the second thickener.

  Moreover, 1-7%: 1-10%: 1-10% may be sufficient as the ratio of the 1st thickener: 2nd thickener: weight% of an active ingredient in the said needle main-body part.

  The ratio of the first thickener: second thickener:% by weight of the active ingredient in the needle body may be 5%: 5%: 5%.

  Moreover, the range of 2: 1 to 3: 1 may be sufficient as the ratio of the thickener and the weight% of an active ingredient in the said needle main-body part.

  Moreover, 1-10%: 1-30%: 1-30% may be sufficient as the ratio of the 1st thickener: 2nd thickener: weight% of an active ingredient in the said active ingredient coating part.

  The ratio of the first thickener: the second thickener:% by weight of the active ingredient in the active ingredient coating portion may be 3%: 30%: 30%.

  The ratio of the thickener and the weight percentage of the active ingredient in the active ingredient coating part may be in the range of 1: 1 to 1: 2.

  The first thickener may be carboxymethylcellulose (CMC), the second thickener may be maltose, and the active ingredient may be lidocaine.

  In addition, the active ingredients contained in the needle body and the active ingredient coating are Lidocaine, Mepivacaine, Prilocaine, Bupivacaine, Etidocaine, Etidocaine, Etidocaine (Procaine), propoxycaine (Propoxycaine), tetracaine (Tetracaine), ropivacaine (Ropivacaine), butacaine (piperocaine), rocaine (ro), procaine Roparacaine) and it may include at least one of dyclonine (Dyclonine).

  The microneedle for dental substance transmission according to another embodiment of the present invention is an active ingredient coating comprising a water-soluble needle main body part and an active ingredient coated on the surface of the needle main body part and transmitted to the oral endothelium organization. Part and a base part that is coupled with the needle body part and bends along the gum shape, and the base part is made of lactic acid-glycolic acid copolymer (PLGA) and polycaprolactone (PCL) from 1: 9 to You may mix by the ratio of 5: 5 weight%.

  According to another embodiment of the present invention, there is provided a method for manufacturing a microneedle for transmitting a dental substance, wherein a microneedle body is formed in a preset shape, and the microneedle body is formed. Forming a base by placing pellets on the mold; separating the base and the main body of the microneedle from the mold; and a thickener and an active ingredient transmitted to the oral endothelium tissue The method may include a step of manufacturing a coating solution in which the microneedles are coated with the coating solution, and a step of drying the microneedle body at room temperature.

  Further, the step of manufacturing the microneedle body portion in a preset shape includes the steps of preparing a mold for molding the microneedle body portion and molding the microneedle body portion. May be included.

  Further, in the step of molding the main body of the microneedle, the thickener and the active ingredient transmitted to the oral endothelium composition are dissolved and filled in the groove formed in the mold, and then the inside is formed by vacuum treatment. The main body of the microneedle may be manufactured by removing air bubbles and leaving only the solution contained in the groove of the mold, followed by natural drying.

  In addition, the step of molding the main body of the microneedle is performed by deionization in a proportion of 1% by weight of carboxymethylcellulose (CMC) 1-7%, maltose 1-10%, and active ingredient (Lidocaine) 1-10%. The solution in water may be filled into the mold groove.

  In addition, the mold includes any one of polydimethylsiloxane (PDMS), a polymer species used for the mold, polyurethane, metal, an aluminum biocompatible material, a water-soluble polymer, and a fat-soluble / amphiphilic polymer. The lipid-soluble polymer and the amphiphilic polymer are HPC (hydroxypropyl cellulose), HPMC (hydroxypropyl methyl cellose), PCL (poly capro lactone), polyglycolide (PGA). , Polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA), PVP (poly vinyl pyrrolidone), PEG (polyethylene glycol), PEO (poly ethyl) ne oxide), PPO (polypropylene oxide), PVME (poly vinyl methyl ether), PMA (poly (methyl) acrylate), Propylene glycol, poly (ester), poly (ester amide) It may include at least one selected from the group consisting of acrylic acid, HA (hyaluronic acid), and gelatin.

  In addition, the step of forming a base part by placing a pellet on a mold in which the main body part of the microneedle is formed includes the step of performing a melting process by placing the pellet on the mold, and performing the melting process. In addition, the method may include a step of removing the bubbles by vacuum processing the pellets and a step of applying a pressure by a sheet pressing machine after the removal of the bubbles is confirmed.

  The pellets are polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polycaprolactone (PCL), polyurethane (PU), At least one selected from the group consisting of polyethylene terephthalate (PET), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA). One may be included.

  The pellet may be prepared by mixing lactic acid-glycolic acid copolymer (PLGA) and polycaprolactone (PCL) in a ratio of 1: 9 to 5: 5% by weight.

  In addition, the step of manufacturing the coating solution may include a step of mixing the thickener and the active ingredient in a preset ratio.

  In addition, the steps of mixing the thickener and the active ingredient at a preset ratio are carboxymethyl cellulose (CMC) 1 to 10%, maltose 1 to 30%, active ingredient (Lidocaine) 1 to 30%. A solution dissolved in deionized water may be produced at a percentage by weight.

  The coating of the coating solution on the microneedle body may be performed by dip coating the coating solution on the microneedle body.

  According to the present invention, a dental substance can be efficiently transmitted into the oral cavity by attaching microneedles to the gums inside the oral cavity that are formed while being refracted into an irregular shape.

  Further, it was determined that there was no pain when the microneedle was applied to the oral cavity, and that there was actually no pain for all users.

  The drug on the surface of the microneedle, that is, the drug coated on the active ingredient coating portion spreads quickly, and the drug inside the microneedle, that is, the drug on the needle body portion contains a large amount of drug. Can do.

  In addition, since the base portion of the microneedle is formed of a flexible material, it can be efficiently bonded to the irregular bent surface of the gum.

  In addition, the microneedle according to the present invention can transmit a fixed amount of an active ingredient within a short time of several seconds or minutes by a single administration.

  Moreover, since the framework of the microneedle is made of a water-soluble substance and part or all melts after administration to the oral endothelium, the risk of contamination can be eliminated.

  Furthermore, it is easy to manufacture water-soluble microneedles, and mass production is possible.

It is sectional drawing of the microneedle for dental substance transmission which concerns on one Embodiment of this invention. 3 is a flowchart illustrating a process of a method for manufacturing a microneedle for transmitting a dental substance according to an embodiment of the present invention. 3 is a flowchart illustrating a process of manufacturing a main body portion of a microneedle for dental substance transmission according to an embodiment of the present invention. FIG. 4A is a perspective view schematically showing a mold for manufacturing a microneedle according to an embodiment of the present invention, and FIG. 4B is a plan view of the mold shown in FIG. It is the figure which showed the form injected in the state which melt | dissolved the raw material for manufacturing a microneedle or biodegradable polymer resin, FIG.4 (c) remains on the mold surface of FIG.4 (b) It is the figure which showed the form which dried the raw material or biodegradable polymer resin. 4 is a flowchart illustrating a process of forming a base portion in a mold in which a main body portion of a microneedle according to an embodiment of the present invention is formed. FIG. 6A is a diagram illustrating a form in which a pellet is placed on a mold in which a main body of a microneedle according to an embodiment of the present invention is formed and melted. FIG. 6B shows that the melted pellet of FIG. 6A is vacuum-treated to remove bubbles, and then a base is formed by applying pressure by a sheet pressing machine. It is a figure. It is the figure which showed the form which isolate | separated the main-body part and base part of the microneedle which concern on one Embodiment of this invention from the mold. 4 is a flowchart illustrating a process of manufacturing a coating solution including an active ingredient of a microneedle for dental substance transfer according to an embodiment of the present invention. It is the figure which showed the shape which immerses the needle main-body part of the microneedle which concerns on one Embodiment of this invention by immersing in the coating solution containing an active ingredient. It is the figure which showed the step which dries the microneedle with which the active ingredient coating part which concerns on one Embodiment of this invention was coated at normal temperature. It is the figure which showed the process of the manufacturing method of the microneedle for dental substance transmission which concerns on one Embodiment of this invention at once in order. Fig. 12 (a) is a diagram showing the shape of a microneedle that can be used on a bent surface of the skin of a conventional face or hand, and Fig. 12 (b) is an embodiment of the present invention. It is the figure which showed the microneedle which bends flexibly along bending | flexion of the gum which concerns on. Fig.13 (a) is the figure which showed the shape where the microneedle which concerns on one Embodiment of this invention bends flexibly, FIG.13 (b) shows the mechanical strength of the microneedle of Fig.13 (a). It is a figure. FIG. 14 (a) is a view showing a form in which the microneedle according to one embodiment of the present invention is inserted into the gum, and FIG. 14 (b) is a bent surface of the gum of FIG. 14 (a). It is the figure which showed the form inserted by bending flexibly along.

  Hereinafter, specific embodiments of the present invention will be described in detail with reference to the drawings. However, the idea of the present invention should not be limited to such an embodiment, and the idea of the present invention may be proposed to be different depending on the addition, change, deletion, and the like of the constituent elements constituting the embodiment. This is also included in the idea of the invention.

  FIG. 1 is a cross-sectional view of a microneedle for dental substance transmission according to an embodiment of the present invention.

  Referring to FIG. 1, a microneedle 1 according to an embodiment of the present invention includes a needle body portion 10, an active ingredient coating portion 20, and a base portion 30.

  The needle body 10 may be formed in a conical shape with a sharp end. The needle body 10 is not particularly limited as long as it can penetrate the skin, but may be formed in a conical shape having a diameter of approximately 1 μm to 100 μm.

  The needle body 10 may be formed of a water-soluble material that dissolves in water. More specifically, when the microneedle 1 is used as a dissolvable microneedle, the needle body 10 is made of a thickening agent such as carboxymethyl cellulose (CMC) having a viscosity and lidocaine (Lidocaine). It may be formed of a material mixed with active ingredients (concepts including dental drugs, the same applies hereinafter) transmitted to the oral mucosa. More specifically, the needle main body 10 itself contains an active ingredient by adding an active ingredient such as lidocaine after being produced by a thickener such as carboxymethyl cellulose (CMC). It becomes like this. By including a thickener in the needle body 10, the mechanical strength of the needle body 10 can be improved.

  On the other hand, when the microneedle 1 is used as a coating microneedle, the needle body 10 has a high biodegradability such as PLA (Poly Lactic Acid) or PLGA (Poly Lactic-co-Glycolic Acid). It may be formed of a molecular resin.

  Thickeners contained in the needle body 10 are carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran (sulfuric acid). , Chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyanhydride, polyolhydride, polyolhydride Etherester, polyesteramide ( oligoesteramide), poly (butyric acid), poly (valeric acid), polyacrylate, poly (ethylene-vinyl acetate) polymer, acrylic substituted cellulose acetate, poly (vinyl chloride), poly (fluoride) Vinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), hydroxy cellulose HP ), Carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, isomaltose, isomaltose, isomaltose , A copolymer of monomers forming these polymers, and at least one selected from the group consisting of cellulose may be included.

  Among these, carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran (sulfuric acid), chitosan, polylysine (polylysine). ), Carboxymethyl chitin, fibrin, agarose, pullulan, polyanhydride, polyorthoester, polyetherester (polyetheramide) polyesteramide , Poly (butyric acid), poly (valeric acid), polyacrylate, ethylene-vinyl acetate polymer, acryl-substituted cellulose acetate, polyvinyl chloride, polyvinylidene fluoride (polyvinyl chloride) Polyvinylidene Fluoride), poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide (polyethylene oxide), polyvinyl pyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), ethyl cellulose (EC), hydroxypropyl cellulose (HPC) Carboxymethyl cellulo Carboxymethyl cellulose and cyclodextrin may be a thickener (first thickener) having relatively low solubility in water, such as maltose, lactose, trehalose, Cellobiose, Isomaltose, Turranose and Lactulose are water-soluble substances with high solubility in water, and even when these concentrations increase, they function as thickeners. In order to achieve, it is good also as a thickener (2nd thickener) with high solubility with respect to water.

  Therefore, the needle body portion 10 is a thickener having low solubility such as carboxymethylcellulose (CMC) and a water-soluble substance such as maltose. A thickener having high solubility and an active ingredient such as lidocaine may be contained as main components.

  The needle body 10 may be manufactured by a method in which a mixture of a thickener and an active ingredient is injected into the mold (M) and molded, or a biodegradable polymer resin is injected into the mold (M) and molded. Good. A detailed manufacturing method of the needle body 10 and a specific material of the mold (M) will be described later.

  The active ingredient coating part 20 is coated on the surface of the needle body part 10. The active ingredient coating portion 20 may be formed of a material in which a thickener such as carboxymethylcellulose (CMC) or maltose and an active ingredient such as lidocaine are mixed in a preset ratio.

  In addition to maltose, the thickener contained in the active ingredient coating part 20 includes lactose, trehalose, cellobiose, isomaltose, turanose, or A thickener having high solubility in water such as lactulose may be included, and a thickener having low solubility such as carboxymethylcellulose (CMC) described above may also be included in a predetermined ratio.

  However, the active ingredient coating part 20 is far more thicker than the needle body part 10 than the thickener such as carboxymethylcellulose (CMC) in which the ratio of the thickener such as maltose is high. It may be too high.

  As described above, for example, an active ingredient such as a dental drug is distributed on the surface of the needle main body 10, that is, the active ingredient coating part 20, so that a fixed amount of the active ingredient (drug) can be rapidly transferred into the oral mucosa or gum. Can be communicated to. Furthermore, since the active ingredient is contained not only in the active ingredient coating part 20 but also in the needle body part 10 having a volume larger than that of the active ingredient coating part 20, it is possible to transmit a large amount of the active ingredient for a long time. There is an effect that the active ingredient can be transmitted over the range.

  Therefore, the minimum active ingredient that must be transmitted to the oral mucosa or gum is contained in the active ingredient coating portion 20 so that it is quickly transmitted to the oral mucosa or gum, and the remaining active ingredient is transferred to the needle body 10. It is preferable to include.

  A detailed process of coating and drying the active ingredient coating portion 20 on the surface of the needle body portion 10 will be described later.

  The thickener such as maltose contained in the active ingredient coating portion 20 has higher solubility than the thickener such as CMC contained in the needle body portion 10, that is, the dissolution rate is fast. After being applied to a gum or the like, the active ingredient (eg, lidocaine) contained in the active ingredient coating part 20 is transmitted to the gums or the oral mucosa faster than the active ingredient contained in the needle body part 10. become.

  Not only the active ingredient coating part 20 but also the needle body part 10 includes maltose, lactose, trehalose, cellobiose, isomaltose, turanose, or lactulose (Tulose). A thickener having a relatively high solubility, such as Lactulose), is contained in the needle body portion 10 at a ratio such a thickener is contained in the active ingredient coating portion 20. Therefore, the active ingredient contained in the active ingredient coating part 20 is transmitted to the gums and the oral mucosa faster than the active ingredient contained in the needle body part 10.

  This is because the transmission rate of the active ingredient is improved as the ratio of the thickener having high solubility such as maltose is higher.

  As an example, if the ratio of the thickener having high solubility such as maltose contained in the needle body 10 is about 5%, the increase in solubility such as maltose contained in the active ingredient coating part 20 is high. The proportion in which the adhesive is included may be about 30%. Therefore, by adjusting the amount of the active ingredient contained in the active ingredient coating part 20 and the amount of the active ingredient contained in the needle body part 10, the rate at which the active ingredient is transmitted to the gums and the oral mucosa is adjusted. Is possible. For example, in order to increase the speed at which an active ingredient such as lidocaine is transmitted to the gums or the mucous membrane in the oral cavity, the amount of the active ingredient contained in the active ingredient coating part 20 is more than the amount of the active ingredient contained in the needle body part 10. On the contrary, in order to relatively slow the rate at which the active ingredient is transmitted to the gums and the mucous membrane in the oral cavity, the amount of the active ingredient contained in the active ingredient coating portion 20 is changed to a needle. It may be less than the amount of the active ingredient contained in the main body 10.

  Further, the active ingredient contained in the active ingredient coating part 20 and the needle body part 10 may be a dental drug. Such active ingredients include lidocaine, mepivacaine, prilocaine, bupivacaine. (Bupivacaine), etidocaine (Etidocaine), articaine (Procaine), propoxycaine (Propacaine), tetracaine (Tetracaine), ropivacaine (Ropivacaine) , Benzocaine, chloroprocaine (C loroprocaine), proparacaine (Proparacaine) and dyclonine (it may include at least one selected from the group consisting of Dyclonine).

  The ratio of the thickener having a relatively low solubility, the thickener having a relatively high solubility, and the active ingredient at the tip of the needle body 10, more precisely the needle body 10, is 5 wt. %: 5% by weight: 5% by weight may be used. As an example, it is preferable that carboxymethyl cellulose (CMC): maltose: lidocaine is contained in the tip portion of the needle body 10 at a ratio of 5 wt%: 5 wt%: 5 wt%.

  Therefore, in the case of the needle body 10, the ratio between the thickener and the active ingredient is in the range of 10: 0 to 1: 9, preferably in the range of 2: 1 to 3: 1.

  In the active ingredient coating part 20, the ratio of the thickener having relatively low solubility, the thickener having relatively high solubility, and the active ingredient is 5% by weight: 30% by weight: 30% by weight. There may be. As an example, it is preferable that the active ingredient coating part 20 contains hydroxypropyl methylcellulose (HPMC): maltose: lidocaine in a ratio of 5 wt%: 30 wt%: 30 wt%.

  Therefore, in the case of the active ingredient coating part 20, the ratio of the thickener to the active ingredient is in the range of 9: 1 to 1: 9, preferably in the range of 1: 1 to 1: 2. The base portion 30 is combined with the needle main body portion 10 and is formed to bend so as to match the shape of the gums, that is, the gums. More specifically, the base part 30 may be formed of a flexible material so as to bend flexibly along the bending of the tooth root.

  The base part 30 is made of polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE: Polytetrafluoroethylene), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA: ethylene). Polycaprolactone (PCL), Polyurethane (PU), Polyethylene terephthalate (PET), Polyethylene glycol (PEG), Polyvinyl alcohol (PVA) At least one selected from the group consisting of Polyvinyl alcohol, PLA (Poly lactide), Lactic acid-glycolic acid copolymer (PLGA), Poly (lactic-co-glycolic acid), and Polyglycolide (PGA). Is included.

  The base portion 30 may contain other polymer excluding polycaprolactone (PCL) and polycaprolactone (PCL) in a ratio of 1: 9 to 5: 5 by weight, more preferably 1: 9 or 2 : 8 may be included.

  In other words, other polymers (other polymers (polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polyurethane (PU) , Polyethylene terephthalate (PET), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA)) Polycaprolactone (PCL) may be included in a ratio of 1: 9 to 5: 5 by weight, preferably in a ratio of 1: 9 or 2: 8.

  As an example, the base portion 30 is made of a lactic acid-glycolic acid copolymer (PLGA) that is easily broken but can maintain mechanical strength, and a polycaprolactone (PCL) having a flexible property in a ratio of 1: 9 to 5: 5. You may make it have all the effect of two substances, mixing in the ratio of weight%.

  Moreover, the base part 30 may be formed only with a polycaprolactone (PCL) material.

  A detailed process of manufacturing the base portion 30 by joining the needle main body portion 10 will be described later.

  FIG. 2 is a flowchart illustrating a process of manufacturing a microneedle for transmitting a dental substance according to an embodiment of the present invention.

  Referring to FIG. 2, in order to manufacture a microneedle for transmitting a dental substance according to an embodiment of the present invention, first, the needle body 10 of the microneedle 1 is manufactured in a preset shape ( S10). Next, the base 30 is formed by placing pellets on the mold (M) in which the needle body 10 of the microneedle 1 is formed (S20). Next, the base 30 and the needle body 10 are separated from the mold (M) (S30). Next, a coating solution of the active ingredient coating part 20 to be coated on the needle body part 10 is manufactured (S40). Next, for example, the coating solution of the active ingredient coating part 20 is dip coated on the needle body part 10 (S50). Next, the microneedle 1 coated with the coating solution of the active ingredient coating unit 20 is dried at room temperature (S60).

  Hereinafter, the respective steps described above will be described in detail with reference to the drawings.

  FIG. 3 is a flowchart illustrating a process of manufacturing a microneedle main body for transmitting a dental substance according to an embodiment of the present invention, and FIG. 4A is a diagram according to an embodiment of the present invention. FIG. 4B is a perspective view schematically showing a mold for manufacturing a microneedle, and FIG. 4B is a raw material or a biodegradable polymer resin for manufacturing a microneedle in the mold of FIG. FIG. 4 (c) shows a form in which the raw material or biodegradable polymer resin remaining on the mold surface in FIG. 4 (b) is dried. FIG.

  3 and 4, the needle body 10 of the microneedle 1 according to an embodiment of the present invention may be manufactured based on a molding. The step S10 of manufacturing the needle body 10 of the microneedle 1 in a preset shape includes a step S11 of preparing a mold (M) for molding the needle body 10 and a step S12 of molding the needle body 10. May be included.

  As described above, the needle body 10 is composed of carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran (sulfuric acid), chitosan, polylysine. , Carboxymethyl chitin, fibrin, agarose, pullulan, polyanhydride, polyorthoester, polyetherester, polyesteric acid, poly (butyric acid), poly (butyric acid), poly (butyric acid), poly (butyric acid), poly (butyric acid), poly (butyric acid) Valeric acid), polyacrylate, ethylene Ethylene-vinyl acetate polymer, acrylic-substituted cellulose acetate, polyvinyl chloride, polyvinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefin, chlorosulfonate polyethylene oxide polyethylene oxide), polyvinylpyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose, cyclodextrin (cyclodd) xtrin, maltose, lactose, trehalose, cellobiose, isomaltose, turanose, lactulose, and monomers forming these polymers You may contain at least 1 selected from the group which consists of a copolymer and a cellulose.

  A plurality of conical grooves may be formed in the mold (M) so that the end of the needle main body 10 is sharpened (see FIG. 4A).

  At this time, the mold (M) is made of polydimethylsiloxane (PDMS), a polymer species used in the mold, polyurethane, metal, aluminum biocompatible material, water-soluble polymer, and fat-soluble polymer or amphiphilic polymer. It is a structure comprising at least one selected from the group consisting of the lipid-soluble polymer and the amphiphilic polymer, such as HPC (hydroxypropyl cell), HPMC (hydroxypropyl cell), PCL (Poly capro lactone), polyglycolide (PGA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA), PVP (poly vinyl pyrrolidone), PEG (polyethylene) lycol), PEO (poly ethylene oxide), PPO (polypropylene oxide), PVME (poly vinyl methyl ether), PMA (poly (methyl) acrylate), Propylene glycol (polypropylene oxide). It may include at least one selected from the group consisting of acrylamide (acrylic acid), acrylic acid, HA (hyaluronic acid), and gelatin.

  More specifically, in the step S12 of molding the needle body 10 of the microneedle 1, a solution in which a thickener such as carboxymethylcellulose (CMC) and an active ingredient transmitted to the oral endothelium composition are dissolved is a PDMS mold ( After filling in M), the internal bubbles may be removed by vacuum treatment.

  More specifically, the first thickener such as carboxymethylcellulose (CMC) is 1 to 7% by weight (5% is appropriate), and the second thickener such as maltose is 1 to 10% by weight (5% is appropriate). ), And filling a solution (Solution) in which 1 to 10% by weight (5% is appropriate) of an active ingredient such as lidocaine in Deionized water is filled in the tip part (the depressed part) of the PDMS mold. Also good.

  Therefore, in the case of the needle body 10, the ratio between the thickener and the active ingredient is in the range of 10: 0 to 1: 9, preferably in the range of 2: 1 to 3: 1.

  Next, the solution remaining on the upper surface of the mold (M) is removed, leaving only the solution contained in the conical groove of the mold (M), and then accommodated in the conical groove of the mold (M). The solution may be naturally dried to produce the needle body 10 of the microneedle 1 (see FIGS. 4B and 4C).

  More specifically, the solution contained in the conical groove of the mold (M) is dried at room temperature (about 25 ° C.) for about 1 hour, and then is heated in an oven at about 70 ° C. for about 1 hour. It may be dried.

  As described above, when only the solution contained in the sharp groove of the mold (M) is left and then naturally dried, as shown in FIG. 4 (c), needles are formed in the plurality of grooves formed in the mold (M). The main body 10 is formed.

  FIG. 5 is a flowchart illustrating a process of forming a base portion in a mold in which a main body portion of a microneedle according to an embodiment of the present invention is formed, and FIG. 6A illustrates an embodiment of the present invention. FIG. 6B is a view showing a form in which a pellet is placed on a mold in which a main body portion of the microneedle is formed, and is melted, and FIG. 6B is a view of a melted pellet ( FIG. 7 is a view showing that a base is formed by applying pressure by a sheet pressing machine after removing bubbles by vacuum processing of the pellet), and FIG. 7 shows an embodiment of the present invention. It is the figure which showed the form which isolate | separated the main-body part and base part of the microneedle which concern on from a mold.

  Referring to FIGS. 5 to 7, the step S <b> 20 of forming the base portion 30 by placing a pellet on the mold (M) in which the needle body portion 10 of the microneedle 1 according to the embodiment of the present invention is formed is as follows. Step S21 in which the pellet (P) is put on the mold (M) and melted, Step S22 in which the pellet (p) is vacuum-treated to remove bubbles after the melt processing, and a sheet compression machine (sheet) after confirming the bubble removal step S23 of applying pressure by pressing machine).

  The pellet (P) is a molding resin particulate material for forming the base portion 30. The pellet (P), which is such a particulate material, is formed from the mold in which the needle body 10 is already formed. It may be placed on (M) (see FIG. 6A).

  The pellets (P) are polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polycaprolactone (PCL), polyurethane (PU), At least one selected from the group consisting of polyethylene terephthalate (PET), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA). One may be included.

  The pellet (P) may contain other polymer excluding polycaprolactone (PCL) and polycaprolactone (PCL) in a ratio of 1: 9 to 5: 5% by weight, more preferably 1: 9 or It may be included at a ratio of 2: 8.

  In other words, other polymers (other polymers (polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polyurethane (PU) , Polyethylene terephthalate (PET), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA)) Polycaprolactone (PCL) may be included in a ratio of 1: 9 to 5: 5 by weight, preferably in a ratio of 1: 9 or 2: 8.

  As an example, the pellet (P) includes a lactic acid-glycolic acid copolymer (PLGA) that is easily broken but can maintain mechanical strength and a polycaprolactone (PCL) having a flexible property in a range of 1: 9 to 5: The base portion 30 may be provided with all the effects of the two substances.

  Moreover, the pellet (P) may be formed only of polycaprolactone (PCL) having a flexible property.

  The pellet (P) placed on the mold (M) may be melt-processed within a temperature range of about 70 to 150 ° C. As an example, the pellet (P) placed on the mold (M) may be melted in a vacuum oven at about 60 to 100 ° C.

  The melt-processed pellet (P) may be subjected to vacuum treatment to remove bubbles. After confirming the removal of the bubbles, the base portion 30 is formed by applying pressure with a 500 g sheet pressing machine. May be. By using the sheet compression processing machine, the base part 30 can be uniformly manufactured on the mold (M), and the needle body part 10 and the base part 30 housed in the groove of the mold (M) are mutually connected. Come to join.

  If the base part 30 is formed on the mold (M) and the base part 30 and the needle main body part 10 are completely combined, the base part 30 and the needle main body part 10 may be separated from the mold (M) (S30). . Therefore, the plurality of needle main body portions 10 are formed in a conical shape on the base portion 30 (see FIG. 7).

  FIG. 8 is a flowchart illustrating a process for manufacturing a coating solution including an active ingredient of a microneedle for dental substance delivery according to an embodiment of the present invention, and FIG. 9 is a flowchart illustrating an embodiment of the present invention. FIG. 10 is a view illustrating a shape in which the needle body of the microneedle according to the embodiment is immersed in a coating solution containing an active ingredient, and FIG. 10 is a diagram illustrating a case where the active ingredient coating part according to an embodiment of the present invention is coated. It is the figure which showed the step which dries the microneedle at normal temperature.

  Referring to FIGS. 8 to 10, the step S40 of manufacturing the coating solution of the active ingredient coating unit 20 to be coated on the needle body 10 includes the step S41 of mixing the thickener and the active ingredient at a preset ratio. And step S42 of filling micro-wells with a coating solution containing such active ingredients.

  In the process of manufacturing the coating solution of the active ingredient coating part 20, the thickener mixed with the active ingredient is carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid). ), Dextran (sulfate), chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyhydride, polyorthoester, polyether ther Polyesteramide, poly (butyric acid), poly (Valeric acid), polyacrylate, ethylene-vinyl acetate polymer, acrylic substituted cellulose acetate, polyvinyl chloride, polyvinylidene fluoride, poly (vinyl) Imidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), hydroxypropylmethylcellulose (HPMC), ethylcellulose (EC), hydroxypropylcellulose (HPC), carboxymethylcellulose (carboxy) ethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, turrose (Turrose) And a copolymer of monomers that form a monomer, and at least one selected from the group consisting of cellulose.

  More specifically, the first thickener such as carboxymethylcellulose (CMC) is 1 to 10% by weight (3% is suitable), the second thickener such as maltose is 1 to 30% by weight (30% is suitable). ), A solution in which 1 to 30% by weight (30% is appropriate) of an active ingredient such as lidocaine is dissolved in deionized water may be filled in a microwell, and the microneedle body may be dip-coated.

  Therefore, in the case of the active ingredient coating part 20, the ratio of the thickener to the active ingredient is in the range of 9: 1 to 1: 9, preferably in the range of 1: 1 to 1: 2.

  At this time, the active ingredients are lidocaine (Lidocaine), mepivacaine, Prilocaine, bupivacaine, etidocaine, Proticain, Procaine Caine (Tetracaine), Ropivacaine (Ropivacaine), Butacaine (Piperocaine), Cocaine (Cocaine), Benzocaine (Chloproecaine) That at least one may include is selected from the group consisting of nine) are as described above.

  The coating solution containing the active ingredient manufactured in this manner is dipped into the coating solution produced by mixing the thickener and the active ingredient with the needle body 10 manufactured by molding. After S50), the needle body 10 coated with such a coating solution may be dried at room temperature (S60).

  FIG. 11 is a view illustrating a manufacturing process of microneedles for transmitting dental substances according to an embodiment of the present invention at once in order.

  (1) A PDMS mold is prepared (see FIG. 11A).

  (2) Carboxymethylcellulose (CMC) 1-7% (5% is appropriate), Maltose 1-10% (5% is appropriate), Active ingredient (Lidocaine) 1-10% (5% is appropriate) The solution (Solution) dissolved in deionized water is filled in the tip of the PDMS mold (the depressed part), dried at room temperature for about 1 hour, and then dried in a 70 degree oven. Dry for 1 hour (see FIG. 11B). In the actual experiment, CMC 5% + Maltose 5% + Lidocaine 5%. FIG. 11 (c) is a view showing the tip (Tip) portion of the needle main body filled in the PDMS mold after the drying is finished.

  (3) Polycaprolactone (PCL) pellets are placed on the mold (base portion) and air bubbles are removed by reducing and pressurizing in a vacuum oven at 60 to 100 degrees. In an actual experiment, when the width of the base was 0.7 cm × 0.7 cm, 0.8 g of polycaprolactone (PCL: Polycaprolactone) pellets were placed thereon, and bubbles were removed in a vacuum oven at 70 ° C. (FIG. 11 ( d)).

  (4) When the bubbles are removed, they are removed from the vacuum oven and cooled while applying pressure by a 500 g steel plate (see FIG. 11 (e)).

  (5) The cooled main body of the microneedle is taken out to complete the main body of the microneedle (FIG. 11 (f)).

  (6) Carboxymethylcellulose (CMC) 1-10% (3% is appropriate), Maltose 1-30% (30% is appropriate), Active ingredient (Lidocaine) 1-30% (30%) The solution dissolved in water is filled into a microwell, and the microneedle body is dip-coated (see FIG. 11 (g)). In the actual experiment, CMC 3% + Maltose 30% + Lidocaine 30% was performed.

  (7) FIG. 11 (h) is a diagram showing a completed microneedle (oral anesthetic flexible microneedle for oral use) for transmitting a dental substance.

<Comparison table of conventional coated microneedles and microneedles for dental substance transmission according to the present invention>

  Fig. 12 (a) is a diagram showing the shape of a microneedle that can be used on a bent surface of the skin of a conventional face or hand, and Fig. 12 (b) is an embodiment of the present invention. It is the figure which showed the microneedle which bends flexibly along the bending | flexion of the gum which concerns, and Fig.13 (a) is the figure which showed the shape in which the microneedle which concerns on one Embodiment of this invention bends flexibly, FIG. (B) is the figure which showed the mechanical strength of the microneedle of Fig.13 (a).

  Referring to FIGS. 12 and 13, the microneedle 1 according to an embodiment of the present invention may be manufactured so as to bend flexibly so as to fit the bending surface of the gingiva.

  In the conventional microneedle, as shown in FIG. 12A, the needle (S) is merely used along the curved surface of the skin of the face or the skin of the hand, and the skin of the face and the hand is bent. It was possible to transmit active ingredients such as drugs by adhering along the surface. The conventional needle (S) is formed so as to bend within an angle range of about 160 to 180 ° so as to adhere flexibly along the curvature of the skin of the face and hands.

  On the other hand, the microneedle 1 according to an embodiment of the present invention has a larger bending angle than the conventional microneedle (S), and flexibly bends along the gingival margin (C), that is, the bending of the gums. It may be formed as follows. As an example, the microneedle 1 according to an embodiment of the present invention may be manufactured in any shape, but is formed to bend within an angle range of about 100 to 165 ° along the bending of the gum. May be.

  Therefore, the microneedle 1 according to an embodiment of the present invention has an advantage that the dental drug can be more effectively transmitted into the gum by being formed of a flexible material suitable for bending the gum.

  FIG. 13B is a diagram showing the mechanical strength of the microneedle 1 according to the present invention, and the needle body 10 includes a thickener such as carboxymethylcellulose (CMC) in the needle body 10. 10 is improved, and as shown in FIG. 13 (b), it can be easily inserted into the gums and the like, and the dental drug can be transmitted.

  Fig. 14 (a) is a view showing a form in which the microneedle according to one embodiment of the present invention is inserted into the gum, and Fig. 14 (b) is a diagram showing that the microneedle in Fig. 14 (a) is bent on the gum. It is the figure which showed the form inserted by bending along the surface flexibly.

  Referring to FIG. 14, the microneedle 1 according to an embodiment of the present invention may be formed so as to be flexibly inserted so as to fit a gum, that is, a curved surface of a gum.

  Referring to FIG. 14 (a), before the microneedle 1 is completely inserted into the gingiva (G), the base part 30 may be kept flat and from the end of the active ingredient coating part 20. It may be inserted along the gingiva (G).

  Next, when the needle body 10 is completely inserted along the gingiva (G), the base portion 30 may bend flexibly along the shape of the curved surface of the gingiva (G) (FIG. 14 ( b)). In particular, the microneedle 1 according to an embodiment of the present invention may be formed of a coated microneedle, and effectively adsorbs the base portion 30 so as to match the irregular bent shape of the gingiva (G) in the oral cavity. As shown, it may be formed of a flexible material.

  Hereinafter, the operation of the microneedle for transmitting a dental substance according to an embodiment of the present invention will be described.

  First, the microneedle 1 may be manufactured with the needle body 10 and the base 30 based on a molding method. At this time, the needle body 10 is mixed with a thickening agent (eg, carboxymethylcellulose) and an active ingredient (eg: lidocaine) having a mechanical strength that can be adsorbed and inserted into the gingiva (G). ) And then air-dried in a state in which bubbles are removed by vacuum treatment.

  Next, in order to form the base portion 30, the pellet (p) is injected into the mold (M) on which the needle main body portion 10 is formed, melted and vacuumed to remove bubbles, and then subjected to sheet compression processing. You may compress using a machine.

  As described above, the base part 30 and the needle body part 10 may be combined on the mold (M) and then separated from the mold (M), and the separated needle body part 10 may be dip coated with the active ingredient coating part 20. The coated microneedle 1 may be manufactured by a process of drying at room temperature.

  In particular, the base portion 30 of the microneedle 1 may be formed of a flexible material (eg, polyethylene) so as to be effectively adsorbed along an irregular bent surface of the gingiva in the oral cavity.

  Therefore, the needle body 10 of the microneedle 1 can be easily adsorbed anywhere on the gingiva (G) in the oral cavity, and the active ingredient (dental drug) contained in the needle body 10 and the active ingredient coating part 20. Can be transmitted effectively.

1: Microneedle 10: Needle body part 20: Active ingredient coating part 30: Base part M: Mold P: Pellet

Claims (18)

A needle body,
An active ingredient coating part coated on the surface of the needle body part and containing an active ingredient transmitted to the oral endothelium tissue;
A base part coupled to the needle body part and bent along the skin shape inside the oral cavity,
The base is made of polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polycaprolactone (PCL), polyurethane (PU), polyethylene At least one selected from the group consisting of terephthalate (PET), polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA). only including,
The needle body part and the active ingredient coating part contain a thickener, and the solubility of the thickener contained in the active ingredient coating part in water is higher than the solubility of the thickener contained in the needle body part in water. A microneedle for dental substance transfer , characterized in that is larger .   The base portion includes polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polyurethane (PU), polyethylene terephthalate (PET), At least one selected from the group consisting of polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA), and polycaprolactone (PCL) The microneedle for dental substance transfer according to claim 1, comprising: 1 to 9 to 5: 5 by weight.   The base portion includes polyethylene (PE), polypropylene (PP), polytetrafluoroethylene (PTFE), polymethyl methacrylate (PMMA), ethylene vinyl acetate (EVA), polyurethane (PU), polyethylene terephthalate (PET), At least one selected from the group consisting of polyethylene glycol (PEG), polyvinyl alcohol (PVA), polylactide (PLA), lactic acid-glycolic acid copolymer (PLGA) and polyglycolide (PGA), and polycaprolactone (PCL) The microneedle for dental substance transfer according to claim 2, comprising a weight percentage of 1: 9 or 2: 8.   The dental base according to claim 2, wherein the base part includes lactic acid-glycolic acid copolymer (PLGA) and polycaprolactone (PCL) in a ratio of 1: 9 to 5: 5% by weight. Microneedle for mass transfer. Said needle body portion further comprises an active ingredient which is transmitted to the mouth cavity skin tissues, microneedles for dental mass transfer according to claim 1.   Thickeners contained in the needle body are carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran (sulfuric acid). , Chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyanhydride, polyolhydride, polyolhydride Etherester, polyesteramide ( oligoesteramide), poly (butyric acid), poly (valeric acid), polyacrylate, poly (ethylene-vinyl acetate) polymer, acrylic substituted cellulose acetate, poly (vinyl chloride), poly (fluoride) Vinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), hydroxy cellulose HP ), Carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, isomaltose, isomaltose, isomaltose The microneedle for dental substance transfer according to claim 5, comprising at least one selected from the group consisting of a copolymer of monomers that form these polymers, and cellulose. The active ingredient coating portion further comprises an active ingredient which is transmitted to the mouth cavity skin tissues, microneedles for dental mass transfer according to claim 6.   Thickeners contained in the active ingredient coating are carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran (sulfuric acid). ), Chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyhydride, olhydride Polyetherester, polyester Polyesteramide, poly (butyric acid), poly (valeric acid), polyacrylate, poly (ethylene-vinyl acetate) polymer, acrylic-substituted cellulose acetate, polyvinyl chloride (polyvinyl chloride), Polyvinylidene fluoride, poly (vinyl imidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinyl pyrrolidone (PVP), hydroxypropyl methyl cellulose (HPMC), ethyl cellulose (EC), ethyl cellulose (EC), Ceruleau (HPC), carboxymethyl cellulose, cyclodextrin, maltose, lactose, trehalose, cellobiose, isomaltose, isomaltose, isomaltose The microneedle for dental substance transfer according to claim 7, comprising at least one selected from the group consisting of lactulose), a copolymer of monomers forming these polymers, and cellulose. Carboxymethylcellulose (CMC), hyaluronic acid, alginic acid, pectin, carrageenan, chondroitin (sulfuric acid), dextran (sulfuric acid) contained in the needle body and the active ingredient coating part. ), Chitosan, polylysine, carboxymethyl chitin, fibrin, agarose, pullulan, polyhydride, olhydride Polyetherester, Polyesteramide, poly (butyric acid), poly (valeric acid), polyacrylate, poly (ethylene-vinyl acetate) polymer, acrylic substituted cellulose acetate, polyvinyl chloride (Polyvinyl Chloride) , Polyvinylidene fluoride, poly (vinylimidazole), chlorosulfonated polyolefins, polyethylene oxide, polyvinylpyrrolidone (PVP), hydroxypropyl methylcellulose (HPMC), ethylcellulose EC Propyl At least one of cellulose (HPC), carboxymethyl cellulose and cyclodextrin is used as the first thickener,
Among the maltose, lactose, trehalose, cellobiose, isomaltose, turanose and lactulose contained in the needle body and the active ingredient coating portion. When at least one is the second thickener,
The ratio of the weight percent of the second thickener to the first thickener in the active ingredient coating portion is greater than the proportion of the weight percent of the second thickener to the first thickener in the needle body portion. The microneedle for transmitting a dental substance according to claim 8 , characterized in that: The ratio of the weight percent of the first thickener: second thickener: active ingredient in the needle main body is 1-7%: 1-10%: 1-10%. 9. A microneedle for transmitting a dental substance according to 9 . 11. The dental according to claim 10 , wherein the ratio of the weight percent of the first thickener: second thickener: active ingredient in the needle main body is 5%: 5%: 5%. Microneedle for mass transfer. 11. The microneedle for transmitting a dental substance according to claim 10 , wherein the ratio of the weight percent of the thickener and the active ingredient in the needle body is in the range of 2: 1 to 3: 1. . The ratio of the first thickener: second thickener:% by weight of the active ingredient in the active ingredient coating part is 1-10%: 1-30%: 1-30%, Item 15. A microneedle for transmitting a dental substance according to Item 9 . The dental composition according to claim 13 , wherein the ratio of the first thickener: second thickener:% by weight of the active ingredient in the active ingredient coating portion is 3%: 30%: 30%. Microneedles for material transfer. [ 14] The micro for the dental substance transmission according to claim 13 , wherein the ratio of the weight percent of the thickener and the active ingredient in the active ingredient coating part is in the range of 1: 1 to 1: 2. needle. Wherein the first thickener is carboxymethyl cellulose (CMC), the second thickener is maltose (Maltose), wherein the active ingredient is lidocaine, which of claims 10 to 15 The microneedle for dental substance transmission according to claim 1.   The active ingredients contained in the needle body and the active ingredient coating are Lidocaine, Mepivacaine, Prilocaine, Bupivacaine, Etidocaine, Etidocaine, Etidocaine, Etidocaine, Etidocaine ), Propoxycaine, tetracaine, ropivacaine, butacaine, piperocaine, cocaine, benzocaine, procaine, benzocaine, procaine Aracaine) and dyclonine includes at least one of (Dyclonine), microneedles for dental mass transfer according to claim 5 or 7. A water-soluble needle body,
An active ingredient coating part coated on the surface of the needle body part and containing an active ingredient transmitted to the oral endothelium tissue;
A base portion coupled to the needle body portion and bent along a gum shape;
The base part is a mixture of lactic acid-glycolic acid copolymer (PLGA) and polycaprolactone (PCL) in a ratio of 1: 9 to 5: 5 wt% ,
The needle body part and the active ingredient coating part contain a thickener, and the solubility of the thickener contained in the active ingredient coating part in water is higher than the solubility of the thickener contained in the needle body part in water. A microneedle for dental substance transfer, characterized in that is larger .